John Vandermosten
Recent Quotes
"PMN anticipates launching its first in-human trial in 2019 of PMN310."
—
John Vandermosten, Zacks Small-Cap Research
(8/22/18)
more >
"We are initiating coverage on PMN."
—
John Vandermosten, Zacks Small-Cap Research
(6/27/18)
more >
"RXII's sd-rxRNA can augment already amazing results in immunotherapy."
—
John Vandermosten, Zacks Small-Cap Research
(12/7/17)
more >
"RXII expects to announce data from its clinical trials later this year and in early 2018."
—
John Vandermosten, Zacks Equity Research
(9/25/17)
more >
"At the current price, we view RVX shares as undervalued, and in a position to provide long-term upside potential
—
John Vandermosten, Zacks Equity Research
(8/2/17)
more >
"We view RVX's shares as undervalued, and in a position to provide long-term upside potential."
—
John Vandermosten, Zacks Equity Research
(6/14/17)
more >
"Our investment thesis for RVX is based on a large and growing underserved market in cardiovascular disease."
—
John Vandermosten, Zacks Equity Research
(3/30/17)
more >
—
John Vandermosten, Zacks Equity Research
(12/16/16)
more >
